

# CORRECTED EXHIBIT 2012

**On Behalf Of:**

Novartis AG and LTS Lohmann Therapie-Systeme AG

**By:**

Raymond R. Mandra  
ExelonPatchIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**NOVEN PHARMACEUTICALS INC.,**  
Petitioner

v.

**NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,**  
Patent Owners

---

*Inter Partes* Review No. 2014-00549

U.S. Patent 6,316,023

DECLARATION OF PROFESSOR ALEXANDER M. KLIBANOV

# TABLE OF CONTENTS

## Contents

I.	QUALIFICATIONS .....	1
II.	MATERIALS CONSIDERED .....	4
III.	SUMMARY OF OPINIONS .....	4
IV.	LEGAL STANDARDS .....	6
V.	THE RELEVANT DATE OF INVENTION, PERSON OF ORDINARY SKILL IN THE ART, AND CLAIM CONSTRUCTION.....	8
A.	Date Of Invention .....	8
B.	A Person Of Ordinary Skill In The Art.....	8
C.	Claim Construction .....	10
VI.	THE STATE OF THE ART .....	12
A.	Dr. Kydonieus’s Opinions On The State Of The Art.....	12
B.	The True State Of The Art.....	16
1.	Drug Formulation Work Is Complex And Antioxidants Are Not Added To Drug Formulations Unless Necessary.....	16
2.	The Art As A Whole Taught That Rivastigmine Was Stable.....	22
3.	Oxidative Degradation Is Formulation Specific .....	27
VII.	THE OXIDATIVE DEGRADATION OF RIVASTIGMINE WAS UNKNOWN IN THE ART .....	28
A.	The Rivastigmine/RA <sub>7</sub> Art Did Not Teach Or Suggest That Rivastigmine Had An Oxidative Degradation Problem.....	29
1.	GB Patent Application 2 203 040 A (“Enz”).....	29
2.	U.S. Patent No. 4,948,807 (“Rosin”).....	33
3.	Elmalem .....	41
B.	The Petitioner’s Structural Theories Are Contradicted By Pharmaceutical Realities.....	71

1.	Oxidation Is A Complex And Poorly Understood Phenomenon.....	72
2.	The Structure Of The Molecule As A Whole Influences Stability .....	75
3.	Dextromethorphan Is Stable And Does Not Require An Antioxidant Under Pharmaceutically Relevant Conditions .....	84
4.	Nicotine Is Not Structurally Similar To Rivastigmine And Does Not Require An Antioxidant In A Transdermal Device .....	86
5.	A POSA Would Not Draw Conclusions About The Stability Of All Amines In All Formulations Based On The Teaching Of Sasaki .....	91
6.	The Inventors Themselves Did Not Predict Stability Problems With Rivastigmine And Discovered A Problem Only After Testing .....	97
C.	Neither Ebert, Nor The Handbook, Nor Kissel Would Have Led A POSA To Include An Antioxidant In Formulations Containing Rivastigmine .....	100
1.	PCT Publication WO 95/24172 (“Ebert”) .....	100
2.	Handbook Of Pharmaceutical Excipients (“Handbook”) .....	106
3.	European Patent Application No. 0 155 229 A2 (“Kissel”) .....	108
VIII.	NO CHALLENGED CLAIM OF THE ’023 PATENT IS OBVIOUS OVER ANY COMBINATION OF PRIOR ART CITED BY THE PETITIONER IN GROUNDS 1-6.....	110

**I, Alexander M. Klibanov, Ph.D., declare as follows:**

**I. QUALIFICATIONS**

1. I am a Novartis Endowed Chair Professor of Chemistry and Bioengineering at the Massachusetts Institute of Technology (“M.I.T.”), where I have been teaching and conducting research for over 35 years. In 2012-2013, I held the Roger and Georges Firmenich Endowed Chair Professorship in Chemistry and Bioengineering, and in 2007-2012, a Novartis Endowed Chair Professorship of Chemistry and Bioengineering at M.I.T. Prior to that, I was a Professor of Chemistry and a Professor of Bioengineering at M.I.T., positions I held from 1988 and 2000, respectively. From 1979 to 1988, I was an Assistant Professor, then Associate Professor, and thereafter a Full Professor of Applied Biochemistry in the Department of Applied Biological Sciences (formerly the Department of Nutrition and Food Science) at M.I.T.

2. I obtained my M.S. in Chemistry from Moscow University in Russia in 1971 and Ph.D. in Chemical Enzymology from the same University in 1974. Thereafter, I was a Research Chemist at Moscow University’s Department of Chemistry for three years. From 1977 to 1979, following my immigration to the

---

<sup>1</sup> Novartis does not decide who receives this position, and this position in no way affects the content of this declaration.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.